User:Mr. Ibrahem/Ambrisentan

Mr. Ibrahem/Ambrisentan
Clinical data
Trade names	Letairis, Volibris, Pulmonext, others
AHFS/Drugs.com	Monograph
MedlinePlus	a612023
License data	EU EMA: by INN; US DailyMed: Ambrisentan; US FDA: Ambrisentan;
Pregnancy; category	AU: X (High risk); ;
Routes of; administration	Oral
Drug class	Endothelin receptor antagonist
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Undetermined
Protein binding	99%
Elimination half-life	15 hours (terminal)
Identifiers
	IUPAC name (2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid;
Chemical and physical data
Formula	C22H22N2O4
Molar mass	378.428 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@@H](Oc1nc(cc(n1)C)C)C(OC)(c2ccccc2)c3ccccc3;
	InChI InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1 ; Key:OUJTZYPIHDYQMC-LJQANCHMSA-N ;
	(verify)

Ambrisentan, sold under the brand name Letairis among others, is a medication used for pulmonary hypertension.^[2] It improved the ability to exercise and slows worsening.^[2] It is not useful in those with pulmonary fibrosis.^[2] It is taken by mouth.^[2]

Common side effects include swelling, palpitations, headache, and constipation.^[2] Other side effects may include anemia, flushing, ringing in the ears, and liver problems.^[3] Use in pregnancy may harm the baby.^[3] It works by blocking the endothelin receptor, specifically the type A endothelin receptor (ET_A).^[1]

Ambrisentan was approved for medical use in the United States in 2007 and Europe in 2008.^[2]^[4] In the United Kingdom it costs the NHS about £1,600 per month.^[3] In the United States this amount costs about 5,100 USD as of 2021.^[5]

References[edit]

^ ^a ^b Vatter H, Seifert V (2006). "Ambrisentan, a non-peptide endothelin receptor antagonist". Cardiovasc Drug Rev. 24 (1): 63–76. doi:10.1111/j.1527-3466.2006.00063.x. PMID 16939634.
^ ^a ^b ^c ^d ^e ^f ^g ^h "Ambrisentan Monograph for Professionals". Drugs.com. Archived from the original on 4 July 2021. Retrieved 21 July 2021.
^ ^a ^b ^c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 195. ISBN 978-0-85711-369-6.
^ "Volibris". Archived from the original on 23 July 2021. Retrieved 21 July 2021.
^ "Ambrisentan Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 10 April 2021. Retrieved 21 July 2021.

[Vat2006-1] Vatter H, Seifert V (2006). "Ambrisentan, a non-peptide endothelin receptor antagonist". Cardiovasc Drug Rev. 24 (1): 63–76. doi:10.1111/j.1527-3466.2006.00063.x. PMID 16939634.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Ambrisentan Monograph for Professionals". Drugs.com. Archived from the original on 4 July 2021. Retrieved 21 July 2021.

[BNF80-3] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 195. ISBN 978-0-85711-369-6.

[EMA2021-4] "Volibris". Archived from the original on 23 July 2021. Retrieved 21 July 2021.

[5] "Ambrisentan Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 10 April 2021. Retrieved 21 July 2021.

[1]

[2]

[3]

[4]

[5]